LT4846B - Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas - Google Patents

Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas Download PDF

Info

Publication number
LT4846B
LT4846B LT2000109A LT2000109A LT4846B LT 4846 B LT4846 B LT 4846B LT 2000109 A LT2000109 A LT 2000109A LT 2000109 A LT2000109 A LT 2000109A LT 4846 B LT4846 B LT 4846B
Authority
LT
Lithuania
Prior art keywords
compound
acceptable salt
prodrug
pharmaceutically acceptable
active metabolite
Prior art date
Application number
LT2000109A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2000109A (en
Inventor
Peter Scott Dragovich
Joseph Timothy Marakovits
Thomas Jay Prins
Jayashree Girish Tikhe
Stephen Evan Webber
Ru Zhou
Theodore O. Johnson
Original Assignee
Agouron Pharmaceuticals,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals,Inc. filed Critical Agouron Pharmaceuticals,Inc.
Publication of LT2000109A publication Critical patent/LT2000109A/xx
Publication of LT4846B publication Critical patent/LT4846B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
LT2000109A 1998-04-30 1999-01-05 Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas LT4846B (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8382898P 1998-04-30 1998-04-30
US9835898P 1998-08-28 1998-08-28
PCT/US1999/000260 WO1999057135A1 (en) 1998-04-30 1999-01-05 Antipicornaviral compounds, their preparation and use

Publications (2)

Publication Number Publication Date
LT2000109A LT2000109A (en) 2001-05-25
LT4846B true LT4846B (lt) 2001-10-25

Family

ID=26769788

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2000109A LT4846B (lt) 1998-04-30 1999-01-05 Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas

Country Status (34)

Country Link
US (3) US6531452B1 (de)
EP (1) EP1073672B1 (de)
JP (1) JP2003526600A (de)
KR (1) KR20010043004A (de)
CN (1) CN1198838C (de)
AP (1) AP2000001934A0 (de)
AT (2) ATE308557T1 (de)
AU (1) AU768539B2 (de)
BG (1) BG104899A (de)
BR (1) BR9910573A (de)
CA (1) CA2326763A1 (de)
DE (2) DE69910762T2 (de)
DK (1) DK1073672T3 (de)
EA (1) EA003856B1 (de)
EE (1) EE200000621A (de)
ES (1) ES2205760T3 (de)
GE (1) GEP20022824B (de)
HK (1) HK1034722A1 (de)
HR (1) HRP20000623A2 (de)
HU (1) HUP0400624A2 (de)
IL (1) IL138609A0 (de)
IS (1) IS5633A (de)
LT (1) LT4846B (de)
LV (1) LV12666B (de)
NO (1) NO20005411L (de)
NZ (1) NZ507633A (de)
OA (1) OA11503A (de)
PL (1) PL351250A1 (de)
PT (1) PT1073672E (de)
SI (1) SI20428A (de)
SK (1) SK284714B6 (de)
TR (1) TR200003159T2 (de)
WO (1) WO1999057135A1 (de)
YU (1) YU66000A (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351250A1 (en) 1998-04-30 2003-04-07 Agouron Pharma Antipicornaviral compounds, their preparation and use
US6355807B1 (en) 1999-08-24 2002-03-12 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
US6774243B2 (en) 1999-08-24 2004-08-10 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
PE20010517A1 (es) * 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
PA8507801A1 (es) * 1999-12-03 2002-08-26 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis
PE20011277A1 (es) 2000-04-14 2002-01-07 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis
MXPA02012456A (es) 2000-06-14 2004-01-26 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y materiales para su sintesis.
WO2004093860A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Inhibitors of sars related coronavirus proteinase
US20040235952A1 (en) * 2003-05-05 2004-11-25 Agouron Pharmaceuticals, Inc. Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
CN1922137A (zh) * 2003-12-31 2007-02-28 太景生物科技股份有限公司 蛋白酶抑制剂
US7462594B2 (en) 2003-12-31 2008-12-09 Taigen Biotechnology Co., Ltd. Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
CN100363346C (zh) * 2004-10-22 2008-01-23 清华大学 冠状病毒主蛋白酶的小分子抑制剂、制备方法及其应用
US7893657B2 (en) * 2006-12-19 2011-02-22 Anand Kumar Chavakula Multi-power charger and battery backup system
KR100891699B1 (ko) 2007-04-10 2009-04-03 광주과학기술원 7-아미노-4-((ｓ)-3-(4-플루오로페닐)-2-((r)-3-메틸-2-(5-메틸이소옥사졸-3-카복사미도)부탄아미도)프로판아미도)-7-옥소-2-헵테노에이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 및 치료용 약학적 조성물
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
JP2011524340A (ja) 2008-05-21 2011-09-01 ニュー・ワールド・ラボラトリーズ・インコーポレイテッド 選択的カスパーゼ阻害剤およびその使用
WO2010133000A1 (en) 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US9944674B2 (en) 2011-04-15 2018-04-17 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
CN102838523A (zh) * 2011-06-23 2012-12-26 南开大学 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
CN103145608B (zh) * 2011-12-07 2015-09-02 南开大学 抗肠病毒71(ev71)己内酰胺类化合物及其制备方法和用途
RU2518314C2 (ru) * 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
CN110105348A (zh) * 2019-03-08 2019-08-09 南开大学 新型迈克尔受体类肠病毒71型抑制剂的制备及用途
CA3139977A1 (en) 2019-06-05 2020-12-10 Raymond F. Schinazi Peptidomimetics for the treatment of coronavirus and picornavirus infections
CA3174069A1 (en) 2020-03-06 2021-09-10 Pfizer Inc. Methods of inhibiting sars-cov-2 replication and treating coronavirus disease 2019
CN116648240A (zh) * 2021-01-22 2023-08-25 中国人民解放军军事科学院军事医学研究院 一种环肽类病毒蛋白酶抑制剂，其制备方法，及其在抗病毒药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856530A (en) 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US5962487A (en) 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US6020371A (en) 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652676A (en) 1985-05-06 1987-03-24 General Foods Corporation L-aminodicarboxylic acid alkenes
JPH06510986A (ja) 1991-06-14 1994-12-08 カイロン　コーポレイション ピコルナウイルスプロテアーゼのインヒビター
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
IT1269511B (it) 1994-05-17 1997-04-01 Univ Degli Studi Milano Derivati di acidi ammino-solfonici , loro impiego nella sintesi di pseudopeptidi e procedimento per la loro preparazione
US5498616A (en) * 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
IT1281031B1 (it) 1995-11-17 1998-02-11 Carlo Chiaves Struttura prefabbricata per la realizzazione di opere costruite a cielo aperto, particolarmente per cavalcavia autostradali,
IL120310A (en) 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
CA2254343A1 (en) * 1996-05-14 1997-11-20 Agouron Pharmaceuticals, Inc. Inhibitors of picornavirus 3c proteases and methods for their use and preparation
WO1997049668A1 (en) 1996-06-13 1997-12-31 Smithkline Beecham Corporation Inhibitiors of cysteine protease
US6331554B1 (en) * 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
WO1998043950A1 (en) * 1997-03-28 1998-10-08 Agouron Pharmaceuticals, Inc. Antipicornaviral compouds, compositions containing them, and methods for their use
PL351250A1 (en) 1998-04-30 2003-04-07 Agouron Pharma Antipicornaviral compounds, their preparation and use
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
JP2003506457A (ja) 1999-08-04 2003-02-18 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗ピコルナウィルス化合物及び組成物、その医薬的使用、並びにその合成のための物質
PE20010517A1 (es) 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
EP1206470A2 (de) 1999-08-24 2002-05-22 Agouron Pharmaceuticals, Inc. Verfahren und zwischenprodukte zur herstellung von isoxazolcarboxamiden und analogen
PA8507801A1 (es) 1999-12-03 2002-08-26 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856530A (en) 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US6020371A (en) 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
US5962487A (en) 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GREEN, WUTZ: "Protecting Groups in Chemical Synthesis (2nd ed.)"

Also Published As

Publication number Publication date
KR20010043004A (ko) 2001-05-25
DE69910762T2 (de) 2004-03-11
HUP0400624A2 (hu) 2004-06-28
LT2000109A (en) 2001-05-25
EA200001133A1 (ru) 2001-08-27
PT1073672E (pt) 2004-01-30
DE69910762D1 (de) 2003-10-02
IL138609A0 (en) 2001-10-31
HRP20000623A2 (en) 2001-04-30
AU2028799A (en) 1999-11-23
NZ507633A (en) 2003-10-31
CN1311793A (zh) 2001-09-05
PL351250A1 (en) 2003-04-07
US6531452B1 (en) 2003-03-11
EP1073672A1 (de) 2001-02-07
GEP20022824B (en) 2002-10-25
CN1198838C (zh) 2005-04-27
EP1073672B1 (de) 2003-08-27
ATE248186T1 (de) 2003-09-15
JP2003526600A (ja) 2003-09-09
SK16042000A3 (sk) 2001-05-10
NO20005411D0 (no) 2000-10-27
US20030130204A1 (en) 2003-07-10
BG104899A (en) 2001-08-31
SI20428A (sl) 2001-06-30
DE69928140D1 (de) 2005-12-08
DK1073672T3 (da) 2003-12-08
LV12666A (en) 2001-05-20
TR200003159T2 (tr) 2001-09-21
LV12666B (lv) 2001-11-20
ATE308557T1 (de) 2005-11-15
SK284714B6 (sk) 2005-09-08
NO20005411L (no) 2000-10-27
OA11503A (en) 2004-05-10
HK1034722A1 (en) 2001-11-02
AP2000001934A0 (en) 2000-12-31
IS5633A (is) 2000-09-22
EA003856B1 (ru) 2003-10-30
AU768539B2 (en) 2003-12-18
ES2205760T3 (es) 2004-05-01
US6995142B2 (en) 2006-02-07
CA2326763A1 (en) 1999-11-11
US20060046966A1 (en) 2006-03-02
BR9910573A (pt) 2001-01-16
WO1999057135A1 (en) 1999-11-11
YU66000A (sh) 2003-12-31
EE200000621A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
LT4846B (lt) Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas
AU779321B2 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US5962487A (en) Antipicornaviral compounds and methods for their use and preparation
AU736550B2 (en) Antipicornaviral compounds, compositions containing them, and methods for their use
US6906198B1 (en) Antipicornaviral compounds, their preparation and use
EP1329457B1 (de) Antipicornavirale Verbindungen, deren Herstellung und Verwendung
MXPA00010406A (en) Antipicornaviral compounds, their preparation and use
CZ20003986A3 (cs) Antipicornavirální součeniny a kompozice, jejich farmaceutické použití a materiály pro jejich syntézu
Obrecht et al. Synthesis, Conformational Properties, and Synthetic Applications of Novel Optically Pure α, α‐Disubstituted (R)‐and (S)‐Glycines (‘α‐Chimeras’) Combining Side Chains of Asp, Glu, Leu, Phe, Ser, and Val

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20050105